Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Saltzman

Orthopaedic Surgery Seattle, WA Medical Doctor

NPI 1699930792 CMS profile 31047

4245 Roosevelt Way Ne, Suite E110, Seattle, WA 98105

Open in the dashboard

General payments

$1,836,961

499 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Saltzman of Seattle, WA is reported in the CMS Open Payments database as having received $1,836,961 across 499 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $315,468 83
2024 General $307,943 87
2023 General $303,002 73
2022 General $240,643 53
2021 General $261,354 92
2020 General $194,803 45
2019 General $213,748 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Saltzman
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Matthew Saltzman were reported at $315,468. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Matthew Saltzman Orthopaedic Surgery median Middle half National median
2019 $213,748 $644 $140–$2,844 $163
2020 $194,803 $312 $75–$1,860 $114
2021 $261,354 $520 $117–$2,495 $132
2022 $240,643 $598 $128–$2,731 $149
2023 $303,002 $461 $128–$2,264 $160
2024 $307,943 $497 $134–$2,475 $164
2025 $315,468 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $1,598,594 394 payments
  2. Stryker Corporation $160,003 47 payments
  3. Wright Medical Technology, Inc. $71,540 18 payments
  4. Arthrex, Inc. $3,522 16 payments
  5. Lightbody Medical Technologies Inc $1,319 4 payments
  6. Medwest Associates $600 3 payments
  7. Shoulder Innovations, Inc. $308 2 payments
  8. Exactech, Inc. $300 2 payments
  9. DePuy Synthes Sales Inc. $227 9 payments
  10. Linvatec Corporation $166 1 payment
  11. Other $382 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $898,533 90 payments
  2. Consulting Fee $821,277 43 payments
  3. Travel and Lodging $70,276 167 payments
  4. Honoraria $30,300 1 payment
  5. Food and Beverage $14,175 196 payments
  6. Education $2,400 2 payments
Products named General payments · program years 2019–2025
  1. PRIMARY SHOULDER Shoulder $884,567 156 payments
  2. Primary Shoulder Orthopedics/Orthopedic Surgery $282,110 45 payments
  3. Shoulder System $275,095 66 payments
  4. AEQUALIS PERFORM $159,578 40 payments
  5. AEQUALIS $71,410 16 payments
  6. NextAR Shoulder $17,299 1 payment
  7. AMISTEM $3,606 32 payments
  8. GMK SPHERE Knee $3,085 26 payments
  9. REVERSE SHOULDER $2,904 46 payments
  10. GMK Sphere Orthopedics/Orthopedic Surgery $732 8 payments
  11. Other $4,409 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

85

Median for Orthopedic Surgery: 203

Drug cost

$582

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 85 $582

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$228,211

Of which drugs: $1,002

Medicare patients

571

Average age 75

Services billed

3,033

323 women, 248 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 72%
High blood pressure 67%
Ischemic heart disease 27%
Diabetes 22%
Osteoporosis 22%
Cancer 21%
Chronic kidney disease 19%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 194 1,330 $1,000

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

499 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record